Nalbuphine reduces the incidence of emergence agitation in children undergoing Adenotonsillectomy: A prospective, randomized, double-blind, multicenter study

• Published in: Journal of clinical anesthesia 2023-05, Vol.85, p.111044-111044, Article 111044
• Main Authors: He, Jian, Zhang, Lei, Tao, Tao, Wen, Xianjie, Chen, Daguang, Zheng, Xueqin, Luo, Changhui, Liang, Hua, Wang, Hanbing
• Format: Article
• Language: English
• Subjects: Analgesics; Anesthesia Recovery Period; Anesthesia, General - adverse effects; Blood pressure; Child; Clinical trials; Delirium; Double-Blind Method; Double-blind studies; Drug dosages; Emergence agitation; Emergence Delirium - epidemiology; Emergence Delirium - etiology; Emergence Delirium - prevention & control; Extubation; General anesthesia; Heart rate; Humans; Incidence; Nalbuphine; Nalbuphine - adverse effects; Pain; Patients; Pediatrics; Postoperative pain; Prospective Studies; Sevoflurane; Surgery
• ISSN: 0952-8180; 1873-4529
• DOI: 10.1016/j.jclinane.2022.111044

To evaluate the effect of nalbuphine on emergence agitation (EA) in children undergoing adenotonsillectomy. Multicenter, prospective, double-blind, randomized controlled trial. The First People's Hospital of Foshan and three other participating institutions in China, from April 2020 to December 2021. Eight hundred patients, 3–9 years of age, American Society of Anesthesiologists (ASA) classification I or II, undergoing elective adenotonsillectomy were included. Nalbuphine (0.1 mg/kg) or saline was administered intravenously. The incidence of EA; the pediatric anesthesia emergence delirium (PAED) scale; and the faces, legs, activity, cry, and consolability (FLACC) scales. Extubation time, duration of post-anesthesia care unit (PACU) stay, anesthesia nurses' and parents' satisfaction, and other side effects. The incidence of EA in the nalbuphine group was lower than that in the saline group 30 min after extubation (10.28% vs. 28.39%, P = 0.000). In addition, the FLACC scores in the nalbuphine group were lower than those in the saline group 30 min after extubation (P 3) was significantly lower in the nalbuphine group than in the saline group (33.58% vs. 60.05%, P = 0.000). Adjusting the imbalance of postoperative pain intensity, the risk of EA was still lower in the nalbuphine group at 0 min (OR, 0.39; 95% CI, 0.26–0.60; P = 0.000), (OR, odds ratio; CI, confidence interval), 10 min (OR, 0.39; 95% CI, 0.19–0.79; P = 0.01), and 20 min (OR, 0.27; 95% CI, 0.08–0.99; P = 0.046) than in the saline group. There were no significant differences in extubation time, duration of PACU stay, nausea and vomiting, or respiratory depression between the two groups (P > 0.05). Nalbuphine reduced the incidence of EA in children after adenotonsillectomy under general anesthesia, which may be involved in both analgesic and non-analgesic pathways. •Nalbuphine could reduce emergence agitation in children after general anesthesia.•Nalbuphine did not increase extubation time and duration of PACU stay.•Nalbuphine did not increase the incidence of breath depression and nausea and vomiting.